Baudax Bio Statistics
Total Valuation
Baudax Bio has a market cap or net worth of 525. The enterprise value is 16.77 million.
| Market Cap | 525 |
| Enterprise Value | 16.77M |
Important Dates
The next estimated earnings date is Friday, February 21, 2025.
| Earnings Date | Feb 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Baudax Bio has 52.46 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 52.46M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +63.63% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 0.00% |
| Float | 52.45M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.00 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.20 |
| EV / Sales | 13.22 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.17 |
Financial Position
The company has a current ratio of 0.07
| Current Ratio | 0.07 |
| Quick Ratio | 0.02 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.56 |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -114.93% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 141,000 |
| Profits Per Employee | -845,444 |
| Employee Count | 9 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.38% in the last 52 weeks. The beta is 1.45, so Baudax Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.45 |
| 52-Week Price Change | -99.38% |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 32.21 |
| Average Volume (20 Days) | 6,594 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.12 |
Income Statement
In the last 12 months, Baudax Bio had revenue of 1.27 million and -7.61 million in losses. Loss per share was -1.91.
| Revenue | 1.27M |
| Gross Profit | -5.74M |
| Operating Income | -35.02M |
| Pretax Income | -58.75M |
| Net Income | -7.61M |
| EBITDA | -34.76M |
| EBIT | -35.02M |
| Loss Per Share | -1.91 |
Balance Sheet
The company has 363,000 in cash and 8.10 million in debt, giving a net cash position of -7.73 million or -0.15 per share.
| Cash & Cash Equivalents | 363,000 |
| Total Debt | 8.10M |
| Net Cash | -7.73M |
| Net Cash Per Share | -0.15 |
| Equity (Book Value) | -1.20M |
| Book Value Per Share | -0.84 |
| Working Capital | -17.71M |
Cash Flow
In the last 12 months, operating cash flow was -14.31 million and capital expenditures -41,000, giving a free cash flow of -14.35 million.
| Operating Cash Flow | -14.31M |
| Capital Expenditures | -41,000 |
| Free Cash Flow | -14.35M |
| FCF Per Share | -0.27 |
Margins
| Gross Margin | n/a |
| Operating Margin | -2,759.89% |
| Pretax Margin | -4,629.39% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Baudax Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2,403.74% |
| Shareholder Yield | -2,403.74% |
| Earnings Yield | -19,085,320.00% |
| FCF Yield | -2,734,829.85% |
Stock Splits
The last stock split was on December 1, 2022. It was a reverse split with a ratio of 0.025.
| Last Split Date | Dec 1, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.025 |
Scores
Baudax Bio has an Altman Z-Score of -19.36. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -19.36 |
| Piotroski F-Score | n/a |